IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issuesNov 3Quarterly updateAlector, Inc.Allogene Therapeutics
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
FDA approves label update for TEPEZZA; Amgen registers MariTide bioavailability studySep 23Weekly roundup, 2 itemsAmgenmaridebart cafraglutide